HC Wainwright Has Negative View of RenovoRx FY2026 Earnings

RenovoRx, Inc. (NASDAQ:RNXT) – Investment analysts at HC Wainwright lowered their FY2026 earnings per share estimates for shares of RenovoRx in a research report issued on Friday, November 6th. HC Wainwright analyst S. Ramakanth now expects that the company will earn ($0.29) per share for the year, down from their previous estimate of ($0.21). The consensus estimate for RenovoRx’s current full-year earnings is ($0.24) per share. HC Wainwright also issued estimates for RenovoRx’s Q4 2026 earnings at ($0.06) EPS, Q1 2027 earnings at ($0.07) EPS, Q2 2027 earnings at ($0.06) EPS, Q3 2027 earnings at ($0.05) EPS, FY2027 earnings at ($0.19) EPS, FY2028 earnings at ($0.03) EPS, FY2029 earnings at $0.08 EPS and FY2030 earnings at $0.18 EPS.

Several other research analysts have also commented on RNXT. Wall Street Zen lowered shares of RenovoRx from a “hold” rating to a “sell” rating in a research note on Monday. Weiss Ratings upgraded shares of RenovoRx from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, September 2nd. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $8.50.

RenovoRx Trading Up 4.4%

Shares of NASDAQ:RNXT opened at $1.18 on Tuesday. The firm’s 50-day moving average is $1.53 and its two-hundred day moving average is $1.11. RenovoRx has a 1 year low of $0.70 and a 1 year high of $2.59.

RenovoRx (NASDAQ:RNXT) last announced its earnings results on Thursday, November 5th. The company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.01). The firm had revenue of $1.07 million for the quarter, compared to analysts’ expectations of $1.06 million. RenovoRx had a negative net margin of 621.71% and a negative return on equity of 135.11%.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in RenovoRx stock. T3 Companies LLC purchased a new position in shares of RenovoRx, Inc. (NASDAQ:RNXT) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 96,800 shares of the company’s stock, valued at approximately $151,000. T3 Companies LLC owned 0.21% of RenovoRx at the end of the most recent reporting period. Institutional investors own 3.10% of the company’s stock.

Key Stories Impacting RenovoRx

Here are the key news stories impacting RenovoRx this week:

• Negative Sentiment: HC Wainwright lowered its FY2026 EPS forecast to a loss of $0.29 from $0.21 and its FY2027 estimate to a loss of $0.19 from $0.04. It also raised projected losses for Q4 2026 and each of the first three quarters of 2027. HC Wainwright Estimates RenovoRx’s Q4 Earnings
• Negative Sentiment: The analyst also reduced longer-term forecasts: FY2028 moved from expected EPS of $0.08 to a loss of $0.03; FY2029 fell from $0.18 to $0.08, and FY2030 from $0.26 to $0.18. Though profitability is still projected in 2029 and 2030, the cuts point to a slower earnings outlook.
• Negative Sentiment: Wall Street Zen lowered its rating on RNXT to “Sell,” adding another bearish signal. RenovoRx Rating Lowered to Sell at Wall Street Zen

RenovoRx Company Profile

RenovoRx, Inc is a clinical-stage biopharmaceutical company developing targeted treatments for solid tumors. The company’s approach is based on its Trans-Arterial Micro-Perfusion (TAMP) platform, which is designed to deliver chemotherapy directly into tumor tissue through the arterial system while limiting exposure to surrounding healthy tissue.

RenovoRx’s lead investigational product, RenovoCath, is a localized drug-delivery system intended to support the administration of anticancer therapies to tumors.